Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Avax Technologies Inc.
DescriptionAutologous haptenized tumor cell vaccine
Molecular Target Not applicable
Mechanism of ActionVaccine
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationMelanoma
Indication DetailsTreat malignant melanoma; Treat melanoma; Treat melanoma after surgical removal of tumor; Treat post-surgical, stage III metastatic melanoma; Treat recurrent melanoma; Treat stage III melanoma after surgery; Treat stage III melanoma as an adjunct to surgery; Treat stage III or IV melanoma; Treat stage IV malignant melanoma; Treat stage IV melanoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today